Skip to main content
Log in

Two reports released by ICER

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. Comparative Effectiveness Public Advisory Council

References

  1. Institute for Clinical and Economic Review. Institute for Clinical and Economic Review Highlights the Clinical Benefits of Using Antiandrogen Therapies to Treat Earlier Stage Prostate Cancer Internet Document : 4 Oct 2018. Available from: URL: https://icer-review.org/announcements/institute-for-clinical-and-economic-review-highlights-the-clinical-benefits-of-using-antiandrogen-therapies-to-treat-earlier-stage-prostate-cancer/

  2. Institute for Clinical and Economic Review. Institute for Clinical and Economic Review Final Report Highlights Uncertainty in Long-Term Safety and Effectiveness of New Treatments for Hereditary Transthyretin Amyloidosis, Discusses Options for Insurance Coverage Criteria Internet Document : 4 Oct 2018. Available from: URL: https://icer-review.org/announcements/institute-for-clinical-and-economic-review-final-report-highlights-uncertainty-in-long-term-safety-and-effectiveness-of-new-treatments-for-hereditary-transthyretin-amyloidosis-discusses-options-for-i/

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Two reports released by ICER. PharmacoEcon Outcomes News 814, 38 (2018). https://doi.org/10.1007/s40274-018-5381-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5381-5

Navigation